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Purpose: A synthetic adrenocorticotropin (ACTH) analog has shown efficacy in Europe as 
primary and secondary therapy for nephrotic syndrome, but there is no published experience 
using the natural, highly purified ACTH gel formulation, available in the United States, for 
nephrotic syndrome. We therefore investigated the use of ACTH gel for nephrotic syndrome 
in the United States.
Patients and methods: Twenty-one patients with nephrotic syndrome treated with ACTH 
gel outside of research settings in the United States, with initiation of therapy by December 31, 
2009, allowing a minimum 6 months follow-up. We defined complete remission as stable renal 
function with proteinuria falling to ,500 mg/day, and partial remission as stable renal function 
with .50% reduction in proteinuria from 500 to 3500 mg/day.
Results: Twenty-one patients with nephrotic syndrome were treated: 11 with idiopathic mem-
branous nephropathy (iMN), 4 with membranoproliferative glomerulonephritis (MPGN), 1 with 
focal segmental glomerulosclerosis (FSGS), 1 with minimal change disease (MCD), 1 with 
immunoglobulin A (IgA) nephropathy, 1 with class V systemic lupus erythematosus (SLE) 
glomerulonephritis, 1 with monoclonal diffuse proliferative glomerulonephritis, and 1 with 
unbiopsied nephrotic syndrome. ACTH was used as primary therapy for 3 patients; the remaining 
patients had previously failed a mean 2.3 immunosuppressive regimens. Eleven patients achieved 
a complete or partial remission, with 4 (19%) in complete remission. Of the 11 patients who 
achieved remission, 9 had iMN, 1 had FSGS, and 1 had IgA nephropathy. Of the 11 patients 
with iMN, 3 (27%) achieved complete remission and 6 (55%) achieved partial   remission despite 
having previously failed a mean 2.4 therapies. Five patients reported   steroid-like adverse 
effects, but there were no severe infections. The limitations were   retrospective data analysis 
with short-term follow-up.
Conclusion: ACTH gel may be a viable treatment option for resistant nephrotic syndrome due to 
membranous nephropathy. Short-term data suggest that remission rates may approach 80%.
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Introduction
Patients with nephrotic syndrome often require immunosuppression to achieve 
  remission, yet many patients either relapse after remission or are resistant to therapy. 
For example, while up to 90% of adults with minimal change disease (MCD) will 
respond to initial therapy with prednisone, approximately one-third of these same 
patients will relapse within 6 months and require further immunosuppression.1,2 With 
diseases such as idiopathic membranous nephropathy (iMN) and focal segmental 
glomerulosclerosis (FSGS), for which first-line therapies produce substantially lower Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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[eGFR], based on serum creatinine) with final proteinuria 
  falling to ,500 mg/day; partial remission as stable or 
improved renal function with $50% reduction in protei-
nuria and final proteinuria 500 to 3500 mg/day; and limited 
response as stable or improved renal function with $50% 
reduction in proteinuria but final proteinuria .3500 mg/day. 
Failure to meet the above criteria was classified as no 
response. Given the small number of patients and the 
observational nature of this study, the data are presented 
descriptively, and no formal statistical analyses were 
performed.
Results
Patient characteristics
In the United States, 25 patients with nondiabetic neph-
rotic syndrome began treatment with ACTH gel before 
December 31, 2009. Data were not available for 4 patients 
with unknown diagnoses. Full data were available for 
21 patients with the following diagnoses (Table 1): iMN 
(n = 11), MPGN (n = 4), FSGS (n = 1), MCD (n = 1), immu-
noglobulin A (IgA)   nephropathy (n = 1), class V systemic 
lupus erythematosus (SLE) glomerulonephritis (n = 1), 
monoclonal diffuse proliferative glomerulonephritis (n = 1), 
and unbiopsied nephrotic   syndrome (n = 1).
ACTH gel was used as primary therapy for only 
3 patients, one each with diagnoses of iMN, IgA   nephropathy, 
and nonbiopsied nephrotic syndrome. The remaining 
18 patients had failed a mean 2.3 immunosuppressive 
regimens prior to ACTH gel therapy, of which 9 patients 
had failed at least 3 prior therapies. Nine of 21 patients 
were female, all but 3 patients were white, and there 
was a wide range of ages (24 to 81 years). Most patients 
had impaired baseline renal function (eGFR range from 
0.2 to .1.0 mL/s/1.73 m2 [11 to .60 mL/min/1.73 m2]) 
with 12 patients demonstrating stage 4 or 5 chronic kidney 
disease (eGFR # 0.5 mL/s/1.73 m2 [#30 mL/min/1.73 m2]). 
  Pretreatment proteinuria ranged from 1340 mg/day to 
18,553 mg/day; only 3 patients had   proteinuria ,4000 mg/day, 
while 11 had   proteinuria .8000 mg/day (Table 2). The 
3 patients whose baseline proteinuria was in subneph-
rotic range exhibited other signs of nephrotic syndrome 
  (hypoalbuminemia, hyperlipidemia, and edema). Mean pre-
treatment albumin (data available for 19 patients) was 29 g/L 
(2.9 g/dL), and mean pretreatment total cholesterol was 
6.10 mmol/L (236 mg/dL) (data   available for 12 patients).
The most common treatment regimen was 80 units subcuta-
neously (SC) twice weekly for 6 months, which was used in 13 
of 21 patients (Table 2). All but 6 were treated for a minimum 
response rates than for MCD, physicians are often compelled 
to use second-, third-, and even fourth-line therapies to 
achieve remission.3–8
In several European studies, tetracosactide, a synthetic 
adrenocorticotropic hormone (ACTH) analog, has shown 
efficacy as primary and secondary therapy for nephrotic 
syndrome. The initial reports came in a case series of patients 
with various etiologies of nephrotic range proteinuria, 
including MCD, iMN, FSGS, and membranoproliferative 
glomerulonephritis (MPGN).9 Subsequently, a randomized, 
controlled study by Ponticelli et al reported similar remis-
sion rates in patients with iMN randomized to synthetic 
ACTH or to therapy with alternating months of steroids and 
cyclophosphamide.10 These reports have generated renewed 
interest in using ACTH as treatment for nephrotic syndrome, 
particularly in patients who are resistant to conventional 
therapies. Synthetic ACTH is not currently available for use 
in the United States, but a natural, highly purified ACTH 
gel formulation (H.P. Acthar® Gel [repository corticotropin 
injection], Questcor   Pharmaceuticals, Inc, Union City, CA, 
USA; abbreviated ACTH gel) is both available and approved 
for use in nephrotic syndrome.
To date, however, there is no modern published experi-
ence on using ACTH gel in nephrotic patients. We therefore 
explored the initial use of ACTH gel for nephrotic syndrome 
in nonresearch settings (ie, by prescription), collecting data 
from treating nephrologists of all known patients in the 
United States whose treatment with this agent was initiated 
by the end of 2009. We describe their clinical course before 
and after treatment with ACTH gel.
Material and methods
In this retrospective case series, we evaluated all known cases 
of idiopathic, nondiabetic nephrotic syndrome treated with 
ACTH gel outside of research settings (ie, by prescription) 
with initiation of therapy by December 31, 2009, allowing a 
minimum of 6 months’ follow-up. Questcor Pharmaceuticals, 
the drug’s manufacturer, provided contact information for 
nephrologists whose patients had ACTH gel prescriptions 
filled during this time period. Treating nephrologists were 
asked to provide data on patients’ demographics,   diagnoses, 
previous immunosuppressive regimens, indications for 
ACTH gel therapy, dosing of ACTH gel, clinical response to 
therapy (creatinine, proteinuria, serum albumin, cholesterol), 
and adverse events from initiation of therapy to most recent 
clinical encounter.
We defined complete remission as stable or improved 
renal function (estimated glomerular filtration rate, GFR Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of 6 months. Five patients treated for fewer than 6 months were 
taken off therapy as a result of clear lack of response; 1 patient 
discontinued therapy due to weight gain but had achieved a 
temporary response while on therapy. The longest treatment 
duration was 14 months, of which the last 2 months included 
a taper of the dose from 40 units twice weekly to 40 units 
once weekly. Most patients stopped treatment without a taper, 
however, and without obvious rebound in proteinuria.
Outcomes
Overall, 11 of 21 patients (52%) achieved a complete or par-
tial remission, with 4 (19%) in complete remission (Table 2). 
One patient achieved a limited response, while 9 patients had 
no overall response to therapy. The patient with class V SLE 
glomerulonephritis transiently responded to therapy (pro-
teinuria declining to ,500 mg/day) but relapsed as soon as 
therapy was stopped, thus not meeting criteria for remission. 
Of the 11 patients who achieved complete or partial remis-
sion, 9 had iMN, 1 had FSGS, and 1 had IgA nephropathy. 
Of the 11 patients with iMN (Figure 1), 3 achieved complete 
remission and 6 achieved partial remission despite having 
previously failed a mean 2.4 therapies. Of the 10 patients with 
nephrotic syndrome diagnoses other than iMN (Figure 2), 
1 patient with IgA nephropathy achieved complete remission, 
Table 1 Characteristics of patients in the United states treated with ACTH gel for nephrotic syndrome through December 31, 2009
Patient Age Gender Race/ 
ethnicity
Diagnosis Previous 
immunosuppression
eGFR 
(mL/min/1.73 m2)
Proteinuria 
(mg/day)
1 59 Male White iMN MMF, CNI .60 4851
2 77 Male Hispanic iMN MMF, CNI 21 6749
3 58 Male White iMN steroids + CTX, CNI, MMF 58 4598
4 55 Male White iMN steroids + CTX, CNI, MMF 57 8153
5 27 Male White iMN steroids, MMF, CNI 30 9000
6 24 Female White iMN None .60 8900
7 75 Female White iMN steroids + CTX .60 3469
8 49 Male White iMN steroids, CNI 25 9150
9 46 Male White iMN steroids + CTX 20 11,911
10 53 Male White iMN steroids, steroids + CTX .60 5700
11 70 Female White iMN steroids, CNI, CTX 40 2625
12 81 Male White MPGN steroids, MMF, rituximab 25 13,073
13 28 Female White MPGN steroids, MMF, rituximab 23 5500
14 53 Female White MPGN steroids, MMF 11 12,398
15 47 Female White MPGN MMF 21 10,244
16 57 Female White MCD steroids, MMF, CNI 15 18,553
17 63 Female Hispanic FsGs steroids, MMF, CNI 33 10275
18 75 Male Black IgA nephropathy None 22 4952
19 32 Female White sLe class V steroids + MMF + CNI .60 1340
20 36 Male White Monoclonal DPGN steroids, rituximab, MMF, CNI 19 8560
21 74 Male White Nsa None 12 5805
Notes: Conversion factor for eGFr: mL/min/1.73 m2 to mL/s/1.73 m2, ×0.01667; aPatient with nephrotic syndrome who did not undergo biopsy for specific diagnosis.
Abbreviations:  CNI,  calcineurin  inhibitor;  CTX,  cyclophosphamide;  DPGN,  diffuse  proliferative  glomerulonephritis;  eGFR,  estimated  glomerular  filtration  rate; 
FsGs, focal segmental glomerulosclerosis; IgA, immunoglobulin A; iMN, idiopathic membranous nephropathy; MCD, minimal change disease; MMF, mycophenolate mofetil; 
MPGN, membranoproliferative glomerulonephritis; Ns, nephrotic syndrome; sLe, systemic lupus erythematosus.
1 patient with FSGS achieved partial remission, and 1 patient 
with MPGN had a limited response to therapy.
Follow-up time for patients ranged from 6 to 14 months. 
Five patients reported steroidlike adverse effects with 
  therapy: 2 patients had impaired blood glucose control, 
2 patients had significant weight gain, and 1 patient showed 
evidence of accelerated bone loss on bone densitom-
etry not observed prior to ACTH gel therapy (Table 3). In 
addition, 1 patient with monoclonal diffuse proliferative 
glomerulonephritis developed acute renal failure within 
1 month of starting   therapy, with creatinine rising from 
327.1 µmol/L (3.7 mg/dL) to 751.4 µmol/L (8.5 mg/dL). 
The drug was stopped along with the patient’s diuretics and 
angiotensin-converting enzyme inhibitor; after intravenous 
fluid   hydration, the creatinine returned to 353.6 µmol/L 
(4.0 mg/dL). Six months after starting ACTH gel, the patient’s 
creatinine ranged between 442.0 and 530.4 µmol/L (5.0 and 
6.0 mg/dL), with transplant evaluation underway. The other 
15 patients reported no adverse events. No severe infections 
were reported in the entire cohort.
Discussion
We present here a retrospective case series evaluating the 
initial experience of 21 patients in the United States treated Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure  1  Changes  in  proteinuria  with  ACTH  gel  therapy  in  11  patients  with 
nephrotic syndrome due to membranous nephropathy.
Abbreviation: ACTH, adrenocorticotropin.
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Figure  2  Changes  in  proteinuria  with  ACTH  gel  therapy  in  10  patients  with 
nephrotic syndrome due to etiologies other than membranous nephropathy.
Abbreviations: ACTH, adrenocorticotropin; FsGs, focal segmental glomerulosclerosis; 
IgA, immunoglobulin A; MCD, minimal change disease; MPGN, membranoproliferative 
glomerulonephritis; Ns, nephrotic syndrome without biopsy; sLe, systemic lupus 
erythematosus
with ACTH gel for nephrotic syndrome. The majority of these 
patients received ACTH as second-, third-, or fourth-line 
therapy for resistant nephrotic syndrome. Idiopathic 
membranous nephropathy was the leading diagnosis among 
these patients and also showed the greatest benefit of therapy, 
with 9 of 11 patients (82%) achieving either complete or 
partial remission. Adverse events associated with therapy 
were relatively minor and included no significant   infections. 
Although 3 patients with other etiologies of nephrotic 
  syndromedemonstrated response to therapy, the early clinical 
data suggest that the drug’s greatest potential benefit may be 
in treating refractory iMN.
Table 2 Dosing, duration, and outcomes of ACTH gel therapy for nephrotic syndrome
Patient Diagnosis ACTH 
gel dose (units)
Duration of ACTH 
therapy
Follow-up 
time
Pre-ACTH 
proteinuria 
(mg/day)
Last proteinuria 
(mg/day)
Outcome
1 iMN 80 sC twice weekly 6 months 8 months 4851 400 Complete remission
2 iMN 80 sC twice weekly 6 months 6 months 6749 1540 Partial remission
3 iMN 80 sC twice weekly 6 months 6 months 4598 1242 Partial remission
4 iMN 80 sC twice weekly 6 months 6 months 8153 1935 Partial remission
5 iMN 80 sC twice weekly 6 months 6 months 9000 3000 Partial remission
6 iMN 80 sC twice weekly 5 months 12 months 8900 6000 No response
7 iMN 40 sC twice weekly 12 months 14 months 3469 34 Complete remission
8 iMN 80 sC q 72 hrs 11 months 11 months 9150 2948 Partial remission
9 iMN 40 sC thrice weekly 6 months 7 months 11911 13,338 No response
10 iMN 40 sC thrice weekly 6 months 6 months 5700 694 Partial remission
11 iMN 80 sC twice weekly 12 months 13 months 2625 240 Complete remission
12 MPGN 80 sC twice weekly 4.5 months 8 months 13073 3741 No responsea
13 MPGN 80 sC twice weekly 4 months 6 months 5500 4825 No response
14 MPGN 40 sC thrice weekly 6 months 6 months 12398 4560 Limited response
15 MPGN 80 sC twice weekly 6 months 6 months 10244 3878 No responsea
16 MCD 80 sC twice weekly 4 months 8 months 18553 18,557 No response
17 FsGs 80 sC twice weekly 6 months 6 months 10275 2970 Partial remission
18 IgA 
nephropathy
40 sC q 72 hrs 8 months 8 months 4952 42 Complete remission
19 sLe class V 40 sC thrice weekly 5 months 8 months 1340 2290 No responseb
20 Monoclonal 
DPGN
80 sC twice weekly 1 month 6 months 8560 8500 No response
21 Ns 40 sC q 72 hrs 6 months 9 months 5805 8708 No response
Notes: aDrop in proteinuria occurred in the setting of significant (.25%) decline in eGFr, thus not meeting criteria for response to therapy; bWhile on ACTH gel therapy, 
proteinuria dropped from 1340 mg/day to 420 mg/day; after patient discontinued therapy due to concerns of weight gain, her proteinuria rebounded to 2290 mg/day.
Abbreviations:  ACTH,  adrenocorticotropin;  DPGN,  diffuse  proliferative  glomerulonephritis;  FsGs,  focal  segmental  glomerulosclerosis;  IgA,  immunoglobulin  A; 
iMN, idiopathic membranous nephropathy; MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; Ns, nephrotic syndrome without biopsy; 
sC, subcutaneous; sLe, systemic lupus erythematosus.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Our observations are concordant with previously 
published reports from Europe using a synthetic ACTH 
analog for nephrotic syndrome due to iMN. Berg and 
Arnadottir, in a seminal paper from 2004, reported the 
results of ACTH   treatment in 23 cases of nephrotic syn-
drome of various   etiologies, including 10 cases of iMN.9 
Half of these iMN patients had previously been treated 
with at least 1 prior immunosuppressive therapy, and all 10 
achieved sustained remission of proteinuria. A more recent 
series from   Germany reported the results of 8 months of 
synthetic ACTH therapy for 4 patients with iMN refractory 
to prior therapies of steroids, cyclosporine, cyclophosph-
amide, mycophenolate mofetil, or azathioprine.11 Within 
the first year, 2 had achieved complete remission, and 2 
had achieved partial remission. The most convincing data, 
however, come from the randomized trial by Ponticelli et al, 
in which 16 patients with iMN received steroids alternating 
with a cytotoxic drug for 6 months versus 16 patients with 
iMN treated with synthetic ACTH for 1 year.10 Most of 
these patients were on renin angiotensin system blocking 
drugs, but none had previously received immunosuppres-
sion. After a median follow-up of 24 months, there were 4 
complete and 8 partial remissions in the steroid/cytotoxic 
therapy group versus 8 complete and 6 partial remissions 
in the ACTH group.
The results presented here, on the other hand, do not 
wholly agree with the successful experiences of Berg and 
Arnadottir in treating nephrotic syndromes other than 
iMN.9 Thirteen of the 23 cases presented in their series 
were nephrotic syndrome diagnoses other than iMN. Only 1 
patient with MPGN did not respond to synthetic ACTH. The 
remaining 12 patients – with diagnoses of MPGN, MCD, 
FSGS, diabetic nephropathy, and hereditary nephritis – all 
experienced at least a 50% reduction in proteinuria during 
synthetic ACTH therapy, and 8 patients achieved sustained 
complete remission (proteinuria , 500 mg/day). In this case 
series, US patients treated with ACTH gel for diagnoses 
other than iMN did not fare as well: for example, only 1 
of 4 MPGN patients demonstrated a limited response. In 
part, this may be due to these patients having worse base-
line renal function and having failed more therapies than 
those reported by Berg and Arnadottir. Notably, 11 of the 
21 patients reported here had advanced renal insufficiency 
(GFR , 0.5 mL/s/1.73 m2 [30 mL/min/1.73 m2]) when 
prescribed ACTH. Eight of these 11 patients were diagnosed 
with diseases other than MN, and their response rate to 
ACTH was generally poor. The lack of response exhibited 
by these patients may reflect the degree of renal failure 
more than the specific diagnosis itself. Theoretically, the 
difference in response could also be explained by inherent 
Table 3 reported adverse events of ACTH gel therapy
Patient Diagnosis ACTH gel dose (units) Duration of ACTH therapy Adverse events
1 iMN 80 sC twice weekly 6 months None
2 iMN 80 sC twice weekly 6 months None
3 iMN 80 sC twice weekly 6 months None
4 iMN 80 sC twice weekly 6 months Hyperglycemia
5 iMN 80 sC twice weekly 6 months None
6 iMN 80 sC twice weekly 5 months Weight gain
7 iMN 40 sC twice weekly 12 months Bone demineralization
8 iMN 80 sC q 72 h 11 months None
9 iMN 40 sC thrice weekly 6 months None
10 iMN 40 sC thrice weekly 6 months None
11 iMN 80 sC twice weekly 12 months Hyperglycemia
12 MPGN 80 sC twice weekly 4.5 months None
13 MPGN 80 sC twice weekly 4 months None
14 MPGN 40 sC thrice weekly 6 months None
15 MPGN 80 sC twice weekly 6 months None
16 MCD 80 sC twice weekly 4 months None
17 FsGs 80 sC twice weekly 6 months None
18 IgA nephropathy 40 sC q 72 h 8 months None
19 sLe class V 40 sC thrice weekly 5 months Weight gain
20 Monoclonal DPGN 80 sC twice weekly 1 month Acute renal failurea
21 Ns 40 sC q 72 h 6 months None
Note: aCreatinine returned to baseline after IV hydration alongside cessation of ACTH gel, diuretics, and angiotensin converting enzyme-inhibitor.
Abbreviations:  ACTH,  adrenocorticotropin;  DPGN,  diffuse  proliferative  glomerulonephritis;  FsGs,  focal  segmental  glomerulosclerosis;  IgA,  immunoglobulin  A; 
MN, idiopathic membranous nephropathy; MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; Ns, nephrotic syndrome without biopsy; 
sC, subcutaneous; sLe, systemic lupus erythematosus.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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differences between the synthetic and natural formulations 
of ACTH.
Although encouraging, the initial results of ACTH gel 
therapy in the United States must be interpreted cautiously in 
light of the limitations of an observational series such as this. 
These patients were not randomized to therapy, and there is 
no comparison or control group against which to interpret 
these results. In some respects, however, the patients may 
serve as their own controls, having failed on average between 
2 and 3 prior immunosuppressive regimens. We did not have 
detailed data on duration of time between prior immunosup-
pressive therapies and initiation of ACTH gel; conceivably, 
if this duration was short, some of the response could be 
attributed to a delay in response to prior agents. In addition, 
the data presented here reflect only short-term follow-up, 
most patients having less than 1 year of follow-up at the time 
of this report. Given that 1 of the patients presented here has 
relapsed off therapy, the follow-up period is likely too short 
to label the remissions as sustained. In previous reports of 
synthetic ACTH therapy, some patients have relapsed but 
responded to second courses of ACTH with good results.9,11 
The short duration of follow-up may also understate adverse 
events in this cohort, which thus far have been mild and 
mostly steroidlike in presentation. Finally, our report does 
not address cost analysis of the various agents available to 
treat the nephrotic syndrome.
These data also do not provide any further understanding 
of the mechanism of action by which ACTH ameliorates pro-
teinuria in the nephrotic syndrome. Speculatively, its better 
performance in iMN than other causes of nephrotic syndrome 
might point to a target of action; eg, antibodies against the 
phospholipase A2 receptor.12 However, a recent study using 
rats with passive Heymann nephritis, an animal model of 
membranous nephropathy, proposes that ACTH may work 
at the melanocortin receptor MC1R in podocytes to reduce 
proteinuria, improve glomerular morphology, and reduce 
oxidative stress.13 This finding suggests that ACTH should 
be equally, if not more, effective in podocytopathies such as 
MCD and FSGS than in iMN. As only 2 of our patients had 
MCD or FSGS, further study of ACTH gel in these conditions 
is clearly warranted.
Conclusion
In conclusion, we present a case series on the initial experience 
in the United States of using ACTH gel as treatment of 
nephrotic syndrome. Overall, 11 of 21 patients –   including 
10 of 18 patients who could be classified as treatment 
  resistant – achieved either complete or partial remission 
with at least 6 months of follow-up. Further, 9 of 11 patients 
with refractory nephrotic syndrome due to iMN achieved 
remission despite having previously failed at least 2 prior 
immunosuppressive regimens. Adverse events were relatively 
few, with no associated infections. This retrospective data 
analysis suggests that further studies are warranted to evalu-
ate ACTH gel in the treatment of nephrotic syndrome.
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